L-DOPA-Induced Dyskinesia

Discover how Melior’s unique phenotypic screening platforms can uncover the untapped value of your candidate therapeutic

The most effective current treatment for Parkinson’s Disease (PD) is dopamine replacement with the dopamine precursor L-DOPA. However, long-term L-DOPA therapy is commonly associated with motor complications that include response fluctuations and involuntary movements called L-DOPA-induced dyskinesia (LID).

This condition can effectively be modeled in rats that have been rendered hemi-parkinsonian by way of a 6-hydroxydopamine (6-OHDA) lesion of the striatum followed by chronic treatment of L-DOPA. Rats subjected to this sequence treatment exhibit abnormal involuntary movements (AIMs) similar to the called L-DOPA-induced dyskinesia (LID) symptoms seen in PD patients.

In the study described below, rats were evaluated for dyskinesia including axial, limb and orolingual AIMs. The recently approved LID therapeutic. Amantadine showed therapeutic benefit by reducing AIMs.

Once daily administration of amantadine (40 mg/kg) significantly reduces AIMs score on day 3 of dosing (A). This effect was sustained until at least day 12 (B) at which point the study was terminated. Data are mean ± SEM; **p<0.01 compared to vehicle. Scores represent the sum of axial, limb and orolingual AIMs at multiple time points over a two hour observation period.

The L-DOPA-Induced Dyskinesia model (LID Model) in normally only conducted in rats. Study durations are typically about one month. Groups sizes of 8-12 animals is ideal.

Interested in running an L-DOPA-Induced Dyskinesia model study?

If you are interested in learning more about Melior’s L-DOPA-Induced Dyskinesia model, please contact us to start the conversation today!

Discuss your project with us

We chose Melior Discovery because they were responsive and cost effective. We are staying with them as a chosen scientific partner because of their thoughtful scientific input to experimental design and attention to detail. Their expertise and flexibility allowed us to quickly adapt the study design and evaluate additional outcome measures to pursue unexpected activity.
Sridharan Rajamani, Ph.D., Senior Research Scientist
Gilead Sciences
I have been working with Melior on a number of projects over the course of a few years now. They have been a great partner throughout this time. The scientists whom I have worked with have been great problem-solvers and were customer focused
Jay Lichter
Avalon Ventures
[We] have been impressed with [Melior’s] ability to rapidly and effectively evaluate compounds in animal models…as we strive to identify compounds to ameliorate the devastating symptoms of Rett,
Monica Coenraads, Executive Director
Rett Syndrome Research Trust
Melior is more than just a service company. Their experienced staff guided us in our drug development efforts. We consider Melior an extension of our own research team.
Josh Schultz
Carolus Therapeutics
Addex Therapeutics has been collaborating with Melior Discovery for more than a year. The studies performed at Melior are always carefully planned and skilfully executed while the progress of the project is well-tracked and communicated to the customer. On several occasions, when testing our compounds in a new in vivo assay, we relied on Melior's scientists in their guidance and advice. We have been particularly pleased with a series of experiments involving assessment of compounds' profiles in the rat sleep/wake EEG. This approach, that has a translational relevance, offered a sensitive measure of a compound's efficacy and side-effects
Mikhail Kalinichev, Ph.D., Associate Research Director
Addex Therapeutics
Having worked with Melior quite extensively over the past several years, we find the team to be highly knowledgeable, responsive and adaptable to our needs. The overall process has been highly efficient and we are impressed by the quality of their reports
Christopher Prior, Ph.D., CEO,
PhaseBio Pharmaceuticals Inc.
…to evaluate our lead compound in an EEG-based sleep wake model. Melior’s very experienced team provided valuable insights and recommendations on study design, analysis and interpretation of the data. As a virtual company, Prexa relied on Melior to become an extension of our knowledge team and they met all our expectations
Pat Baskin and Ev Graham
Prexa Pharmaceuticals
State of-the-art Preclinical Pharmacology
Melior provided State-of-the-art Preclinical Pharmacology Support for a period of nearly a year where a series of in vivo studies were completed on a weekly basis. The staff was extremely user-friendly and the operational processes were excellent. I can recommend Melior without reservation.
Richard DiMarchi, PhD
Cox Professor of Chemistry & Gil Chair in Biomolecular Sciences Indiana University, Department of Chemistry